科济药业

The updated results of zevorcabtagene autoleucel (zevor-cel; R&D code: CT053, an autologous CAR T-cell product targeting BCMA) and CT071 (an autologous CAR T-cell product targeting GPRC5D) have been presented at the 29th Annual Congress of the European Hematology Association (“EHA”). https://lnkd.in/gEKkNrwb #cartcelltherapy #eha2024 #multiplemyeloma #bcma #gprc5d #carcelerate

The preliminary results of Phase I of CT071 (NCT05838131) were presented as a poster at the 29th EHA Annual Congress on June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple myeloma (RRMM)" https://lnkd.in/g3R_eYun #eha #eha2024 #rrmm #cartcelltherapy #gprc5d

The final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in Nature Medicine on June 3, 2024. Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting. https://lnkd.in/gnsCAqeq

The abstracts of zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product against BCMA) and CT071, an autologous CAR T-cell therapy candidate targeting G protein-coupled receptor class C group 5 member D (GPRC5D), have been accepted for oral presentation and poster presentation, respectively, at the 29th Annual Congress of the European Hematology Association (“EHA”). https://lnkd.in/gKvJ8XEc #EHA #hematology #cartcells #cartcelltherapy #multiplemyeloma

An abstract of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against Claudin18.2) has been accepted for oral presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting 2024. Abstract Title Claudin18.2-Targeted Chimeric Antigen Receptor T Cell-Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial https://lnkd.in/gMjEjdr7 #ASCO2024 #cartcell #cartcelltherapy #oncology #gastriccancer #gastrointestinalcancer

"In 2023, CARsgen remained dedicated to our vision, 'Making Cancer Curable' and were committed to reinforcing our team and improving operational efficiency. We made substantial progresses in the regulatory and clinical development of our innovative products and the advancement of new technology platforms. Multiple important milestones for different product candidates across clinical, regulatory, and business development were achieved. We are optimistic that we will navigate and overcome the challenges ahead with resilience and determination, advancing our innovative cell therapies." said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics. https://lnkd.in/gbe6KvNC

The National Medical Products Administration ("NMPA") of China has approved the New Drug Application ("NDA") for zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product candidate against BCMA), for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent). https://lnkd.in/gag2uvdh. #cartcelltherapy #multiplemyeloma

At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ("ASCO GI"), CARsgen presented a poster with study results for satricabtagene autoleucel ("satri-cel", R&D code: CT041, an autologous CAR-T product candidate against Claudin18.2), which include the dose escalation results of the Phase 1b ELIMYN18.2 study (Cohort A) in gastric/gastroesophageal (GC/GEJ) or pancreatic cancer (PC) in the US. https://lnkd.in/gCHDQ-af #cartcelltherapy #gastriccancer #pancreaticcancer

CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma who are at high risk of recurrence after surgical resection. https://lnkd.in/g7JeuUcF